Indivior Plc's SUBLOCADE® Shows Promising Results in Opioid Use Disorder Treatment

Innovative Breakthrough in Opioid Use Disorder Treatment: Indivior’s SUBLOCADE® Demonstrates Efficacy

Indivior PLC announces promising outcomes from a recent randomized, double-blind clinical trial regarding its product SUBLOCADE® (extended-release buprenorphine), as published in JAMA Network Open. The study reveals that both the 100 mg and 300 mg monthly maintenance doses significantly enhance opioid abstinence among individuals grappling with moderate-to-severe opioid use disorder (OUD). The findings are particularly timely, given the ongoing opioid crisis exacerbated by the prevalence of fentanyl in the drug supply. With participants reporting a dramatic decrease in opioid use—from over 43 instances per week at screening to fewer than three instances by week three—the results underscore the potential of SUBLOCADE in facilitating recovery for those affected by this devastating condition.

The trial’s post-hoc analyses highlight that the 300 mg dose is especially advantageous for individuals with high-frequency fentanyl use, yielding notably higher abstinence rates compared to the 100 mg dose. This distinction is critical considering the increasing challenges healthcare providers face in treating patients with complex substance use issues, particularly in the context of potent and dangerous opioids like fentanyl. Christian Heidbreder, Ph.D., Indivior’s Chief Scientific Officer, emphasizes the relevance of these findings for clinicians, noting that they can provide a more tailored approach to treating OUD, especially as the opioid epidemic continues to evolve.

While the trial does report a higher incidence of mild to moderate injection-site reactions in the 300 mg group, these do not lead to treatment discontinuation, suggesting that the benefits of the dosage may outweigh the risks for many patients. However, the study does acknowledge limitations, including the exploratory nature of post-hoc analyses, which were not included in the original statistical analysis plan. As SUBLOCADE is positioned as part of a comprehensive treatment approach that encompasses counseling and psychosocial support, these findings may pave the way for improved clinical practices in addressing opioid addiction.

In addition to the promising trial results, the ongoing commitment of Indivior to enhance treatment options for OUD is evident. The company continues to emphasize the importance of comprehensive care, reinforcing that SUBLOCADE should be integrated into broader treatment strategies to maximize its effectiveness.

Furthermore, Indivior remains vigilant about the risks associated with SUBLOCADE, particularly the severe harm or fatality that could result from intravenous administration, as the formulation solidifies upon such use. This cautionary note serves as a reminder of the complexities involved in treating OUD and the critical need for ongoing education and support for both healthcare providers and patients.